Martin T King, MD, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital

Martin T King, MD, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Radiation Oncology, Harvard Medical School
  • Physician, Radiation Oncology, Dana-Farber Cancer Institute
  • Physician, Radiaton Oncology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Martin King is an expert in prostate and gynecologic brachytherapy. He is interested in identifying therapeutic strategies that can improve quality of life for men receiving radiation therapy for prostate cancer. He is the principal investigator of a multi-center randomized controlled trial, which evaluates whether a novel second-generation anti-androgen Darolutamide can be utilized in place of traditional androgen deprivation therapy for preserving erectile function while not sacrificing the potential for long-term disease control. Patients will be stratified by a genomic classifier as well as extreme radiation dose-escalation (e.g. brachytherapy boost). Other areas of research interest involve radiation for radiorecurrent prostate cancer, as well as therapeutic de-escalation of combination radiation treatments for unfavorable risk prostate cancer. Dr. King is part of the Brachytherapy Clinical Operations Leadership Team, and is an assistant professor of radiation oncology at Harvard Medical School. He is heavily involved in teaching medical students and residents the radiotherapeutic management of prostate and gynecologic cancers with external beam radiation therapy and brachytherapy.

Publications

Powered by Harvard Catalyst
  • Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw 2019; 17:941-948. PubMed
  • Muralidhar V, Mahal BA, Butler S, Lamba N, Yang DD, Leeman J, D'Amico AV, Nguyen PL, Trinh QD, Orio PF, King MT. Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer. J Urol 2019. PubMed
  • Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol 2018; 75:35-41. PubMed
  • Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med 2019; 380:2070-2072. PubMed
  • King MT, Nguyen PL, D'Amico AV, Orio PF. Reply to Partial gland therapy for prostate cancer. Cancer 2018. PubMed
  • King MT, Nguyen PL, Boldbaatar N, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV, Orio PF. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer 2018. PubMed
  • Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys 2018; 100:53-58. PubMed
  • King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol 2017. PubMed
  • Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF, King MT. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 99:904-911. PubMed
  • Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer 2017. PubMed
  • King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy 2019; 18:186-191. PubMed
  • King MT, Nguyen PL, Boldbaatar N, Yang DD, Muralidhar V, Tempany CM, Cormack RA, Hurwitz MD, Suh WW, Pomerantz MM, D'Amico AV, Orio PF. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy 2019; 18:198-203. PubMed
Hide